The prognostic significance of pretreatment [18F]FDG-PET/CT imaging in patients with uterine cervical cancer: preliminary results

Purpose of Investigation: To evaluate the prognostic significance of positron emission tomography/computed tomography (PET/CT) in patients diagnosed with cervical cancer. Materials and Methods: Patients with cervical cancer in FIGO Stages IB1 to IVB were imaged with PET/CT prior to treatment during one of the staging work-ups. The patients were observed for a median of 31.4 months (range, six to 89 months) after the initial treatment. The standardized uptake value (SUV) max of the primary cervical tumor mass was compared with the prognostic factors. Results: A total of 81 patients who were primarily treated with radical hysterectomy (RH, n=45) or concurrent chemoradiation (CCRT, n=36) were analyzed. Multivariate analysis indicated that larger tumor size (> 4 cm, OR 8.694, 95% CI, 1.638-46.146), deep stromal invasion (≥ 1 cm, OR 7.249, 95% CI, 1.141-46.039) by the primary tumor, and pathologically confirmed pelvic lymph node involvement (positive, OR 14.586, 95% CI, 2.072-102.674) were significantly associated with recurrence after treatment. However, pretreatment SUVmax was not a significant independent predictor of disease recurrence (OR 1.058, 95% CI, 0.255-4.398). Conclusion: [18F]Fluorodeoxyglucose (FDG) uptake by the primary tumor showed a significant association with several risk factors that have been identified as treatment predictors. However, a high pretreatment SUVmax was not predictive of recurrence in uterine cervical cancer patients.

FDG-PET/CT; SUVmax; Uterine cervical cancer; Recurrence; Prognostic factor.

[1] Kim Y.T.: “Current status of cervical cancer and HPV infection in Korea”. J. Gynecol. Oncol., 2009, 20, 1.

[2] Chung H.H., Nam B.H., Kim J.W., Kang K.W., Park N.H., Song Y.S., et al.: “Preoperative [18F]FDG PET/CT maximum standardized uptake value predicts recurrence of uterine cervical cancer”. Eur. J. Nucl. Med. Mol. Imaging, 2010, 37, 1467.

[3] Waggoner S.E.: “Cervical cancer.” Lancet, 2003, 361, 2217.

[4] Benedet J.L., Odicino F., Maisonneuve P., Beller U., Creasman W.T., Heintz A.P., et al.: “Carcinoma of the cervix uteri”. J. Epidemiol. Biostat., 2001, 6, 7.

[5] Landoni F., Maneo A., Colombo A., Placa F., Milani R., Perego P., et al.: “Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer”. Lancet, 1997, 350, 535.

[6] Chung C.K., Nahhas W.A., Stryker J.A., Curry S.L., Abt A.B., Mortel R.: “Analysis of factors contributing to treatment failures in stages IB and IIA carcinoma of the cervix”. Am. J. Obstet. Gynecol., 1980, 138, 550.

[7] van Nagell J.R., Jr., Donaldson E.S., Wood E.G., Parker J.C., Jr.: “The significance of vascular invasion and lymphocytic infiltration in invasive cervical cancer”. Cancer, 1978, 41, 228.

[8] Delgado G., Bundy B., Zaino R., Sevin B.U., Creasman W.T., Major F.: “Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study”. Gynecol. Oncol., 1990, 38, 352.

[9] Boyce J., Fruchter R.G., Nicastri A.D., Ambiavagar P.C., Reinis M.S., Nelson J.H., Jr.: “Prognostic factors in stage I Carcinoma of the cervix”. Gynecol. Oncol., 1981, 12, 154.

[10] Werner-Wasik M., Schmid C.H., Bornstein L., Ball H.G., Smith D.M., Madoc-Jones H.: “Prognostic factors for local and distant recurrence in stage I and II cervical carcinoma”. Int. J. Radiat. Oncol. Biol. Phys., 1995, 32, 1309.

[11] Horn L.C., Fischer U., Raptis G., Bilek K., Hentschel B.: “Tumor size is of prognostic value in surgically treated FIGO stage II cervical cancer”. Gynecol. Oncol., 2007, 107, 310.

[12] Chung H.H., Kim J.W., Han K.H., Eo J.S., Kang K.W., Park N.H., et al.: “Prognostic value of metabolic tumor volume measured by FDG-PET/CT in patients with cervical cancer”. Gynecol. Oncol., 2011, 120, 270-4.

[13] Rose P.G., Adler L.P., Rodriguez M., Faulhaber P.F., Abdul-Karim F.W., Miraldi F.: “Positron emission tomography for evaluating paraaortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study”. J. Clin. Oncol., 1999, 17, 41.

[14] Chung H.H., Kim S.K., Kim T.H., Lee S., Kang K.W., Kim J.Y., et al.: “Clinical impact of FDG-PET imaging in post-therapy surveillance of uterine cervical cancer: from diagnosis to prognosis”. Gynecol. Oncol., 2006, 103, 165.

[15] Chung H.H., Jo H., Kang W.J., Kim J.W., Park N.H., Song Y.S., et al.: “Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence”. Gynecol. Oncol., 2007, 104, 529.

[16] Xue F., Lin L.L., Dehdashti F., Miller T.R., Siegel B.A., Grigsby P.W.: “F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy”. Gynecol. Oncol., 2006, 101, 147.

[17] Schwarz J.K., Siegel B.A., Dehdashti F., Grigsby P.W.: “Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma”. JAMA, 2007, 298, 2289.

[18] Lee Y.Y., Choi C.H., Kim C.J., Kang H., Kim T.J., Lee J.W., et al.: “The prognostic significance of the SUVmax (maximum standardized uptake value for F-18 fluorodeoxyglucose) of the cervical tumor in PET imaging for early cervical cancer: preliminary results”. Gynecol. Oncol., 2009, 115, 65.

[19] Pecorelli S.: “Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium”. Int. J. Gynaecol. Obstet., 2009, 105, 103.

[20] Wertheim M.S., Hakes T.B., Daghestani A.N., Nori D., Smith D.H., Lewis J.L., Jr.: “A pilot study of adjuvant therapy in patients with cervical cancer at high risk of recurrence after radical hysterectomy and pelvic lymphadenectomy”. J. Clin. Oncol., 1985, 3, 912.

[21] Samlal R.A., van der Velden J., Schilthuis M.S., Gonzalez Gonzalez D., Ten Kate F.J., Hart A.A., et al.. “Identification of high-risk groups among node-positive patients with stage IB and IIA cervical carcinoma”. Gynecol. Oncol., 1997, 64, 463.

[22] Fuller A.F., Jr., Elliott N., Kosloff C., Hoskins W.J., Lewis J.L. Jr.: “Determinants of increased risk for recurrence in patients undergoing radical hysterectomy for stage IB and IIA carcinoma of the cervix”. Gynecol. Oncol., 1989, 33, 34.

[23] Brooks R.A., Rader J.S., Dehdashti F., Mutch D.G., Powell M.A., Thaker P.H., et al.: “Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer”. Gynecol. Oncol., 2009, 112, 104.

[24] Chou H.H., Chang H.P., Lai CH., Ng K.K., Hsueh S., Wu T.I., et al.: “(18)F-FDG PET in stage IB/IIB cervical adenocarcinoma/adeno-squamous carcinoma”. Eur. J. Nucl. Med. Mol. Imaging, 2010, 37, 728.

[25] Kidd E.A., Siegel B.A., Dehdashti F., Grigsby P.W.: “The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival”. Cancer, 2007, 110, 1738.

[26] Crivellaro C., Signorelli M., Guerra L., De Ponti E., Buda A., Dolci C., et al.: “18F-FDG PET/CT can predict nodal metastases but not recurrence in early stage uterine cervical cancer”. Gynecol. Oncol., 2012, 127, 131.

[27] Grigsby P.W., Siegel B.A., Dehdashti F.: “Lymph node staging by positron emission tomography in patients with carcinoma of the cervix”. J. Clin. Oncol., 2001, 19, 3745.

[28] Signorelli M., Guerra L., Montanelli L., Crivellaro C., Buda A., Dell’Anna T., et al.: “Preoperative staging of cervical cancer: is 18- FDG-PET/CT really effective in patients with early stage disease?” Gynecol. Oncol., 2011;123:236-40.